July 16, 2024

Political Commentary

News Politics Business Sports

3 Reasons to Buy CRISPR Therapeutics Stock Like There’s No Tomorrow

2 min read

investors look at tablet outside

CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year — and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their blood disorders candidate, exa-cel, and investors bet on potential regulatory approvals to follow.

In recent weeks, investors won that bet. Regulators in the U.K. authorized exa-cel — to be commercialized as Casgevy — for sickle cell disease and beta thalassemia. U.S. regulators approved the gene-editing treatment for sickle cell and aim to issue a decision on the second blood disorder early next year.

All of this marks just the beginning of a great opportunity for long-term investors. Let’s check out three reasons to buy CRISPR Therapeutics like there’s no tomorrow.

Two investors look at something on a tablet outdoors.Two investors look at something on a tablet outdoors.

Image source: Getty Images.

1. The regulatory vote of confidence

The recent regulatory nods for Casgevy represent more than just an OK to go ahead and sell the product. These decisions also may be seen as a vote of confidence in a new technology. The U.K. decision was the world’s first authorization of a treatment based on CRISPR gene editing.

Regulators often consider new technologies with an extra layer of caution, so the fact that they have given Casgevy a thumbs up means CRISPR Therapeutics has made it over a particularly difficult hurdle. And as real-world data from Casgevy accrues, we could imagine regulators gaining confidence about the technology.

This is great news for CRISPR Therapeutics because the company’s pipeline is based on CRISPR gene editing — and now we know regulators are willing to let these types of products enter the commercial market.

2. A new focus on next-generation candidates

CRISPR Therapeutics recently said it’s shifting its focus to its next-generation immuno-oncology candidates and dropping its initial ones — including a candidate that was in late-stage development.

The bad news is shelving the late-stage candidate may slow the time to market, but…

2023-12-20 05:00:00

All news and articles are copyrighted to the respective authors and/or News Broadcasters. VIXC.Com is an independent Online News Aggregator

Read more from original source here…

Leave a Reply

Copyright © All rights reserved. | Newsphere by AF themes.